You just read:

Aspyrian Therapeutics, Inc. closes $15.1M as part of a Series B-1 financing to support the advancement of its proprietary precision targeted therapy, RM-1929, to late stage clinical development and the progression of new proprietary immune oncology assets into the clinic.

News provided by

Aspyrian Therapeutics, Inc.

Jul 19, 2017, 18:43 ET